Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHM03 in moderate to severe glabellar lines
NCT06199336Phase 2Completed
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in glabellar lines, sponsored by Junhemeng Biopharmaceutical. Started Jan 2024; status: completed.
02
Drugs
JHM03
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06199336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199336.